Opus Genetics (IRD) Change in Accured Expenses (2010 - 2026)
Opus Genetics (IRD) reported Change in Accured Expenses of $432000.0 for Q1 2026, up 58.82% year-over-year from $272000.0 in Q1 2025, and up 149.48% quarter-over-quarter from -$873000.0 in Q4 2025.
Opus Genetics (IRD) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has 17 years of Change in Accured Expenses data on file, last reported at $432000.0 in Q1 2026.
- Change in Accured Expenses for Q1 2026 came in at $432000.0, up 58.82% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.3 million (down 179.08% YoY), and the FY2025 annual result was -$3.5 million, down 161.59% from the prior year.
- Change in Accured Expenses rose to $432000.0 in Q1 2026 per IRD's latest filing, from -$873000.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $2.4 million in Q4 2024 and troughed at -$1.9 million in Q2 2025.
- A 5-year average of $157882.4 and a median of $1000.0 in 2022 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2023 and 2025: Change in Accured Expenses jumped 149700.0% in 2023, then slumped 1109.94% in 2025.
- A 5-year view of Change in Accured Expenses shows it stood at $461000.0 in 2022, then sank by 125.16% to -$116000.0 in 2023, then soared by 2129.31% to $2.4 million in 2024, then plunged by 137.09% to -$873000.0 in 2025, then soared by 149.48% to $432000.0 in 2026.
- Business Quant data shows IRD's Change in Accured Expenses at $432000.0 in Q1 2026, -$873000.0 in Q4 2025, and -$946000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 931,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Opus Genetics | 355.39 Mn | 295.43 Mn | - | 432,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 432,000.00 |
| Mar 31, 2026 | 432,000.00 |
| Dec 31, 2025 | -873,000.00 |
| Dec 31, 2025 | -873,000.00 |
| Sep 30, 2025 | -946,000.00 |
| Sep 30, 2025 | -946,000.00 |
| Jun 30, 2025 | -1.95 Mn |
| Jun 30, 2025 | -1.95 Mn |
| Mar 31, 2025 | 272,000.00 |
| Mar 31, 2025 | 272,000.00 |
| Dec 31, 2024 | 2.35 Mn |
| Dec 31, 2024 | 2.35 Mn |
| Sep 30, 2024 | 1.75 Mn |
| Sep 30, 2024 | 1.75 Mn |
| Jun 30, 2024 | -161,000.00 |
| Jun 30, 2024 | -161,000.00 |
| Mar 31, 2024 | 1.73 Mn |
| Mar 31, 2024 | 1.73 Mn |
| Dec 31, 2023 | -116,000.00 |
| Dec 31, 2023 | -116,000.00 |